Jazz Pharmaceutical

One of the companies that presented at the biotech conference I attended last week was Jazz Pharmaceutical (JAZZ):

1) They currently have a sleep order treatment which is in Phase III testing.

2) They have recently achieved profitability.

3) They have recently achieved $100 million in net sales for the first time.

4) They are working on a treatment for Fibromyalgia. The Phase II test of this product met its endpoint requirements. Jazz expects to submit an NDA (New Drug Application) later this year. This product has a larger potential market than their sleep disorder treatments have.

5) Jazz has reduced expenses significantly.

6) The company was EBITDA positive for the first time in the second quarter of 2009 and expects to be EBITDA positive for the full year. EBITDA is net income with taxes, depreciation and amortization added back in. This is a non-GAAP accounting measure used to compare companies in the same sector without allowing financing decisions to confuse the issue.

Please note that this is NOT a recommendation to buy these shares. Do your homework! JAZZ closed this past Friday at $9.50 a share.